$Pfizer(PFE)$There is no logic to this when we consider how in relation to covid only, (a) revenue from vaccines are increasing with recent fda approvals for booster shots, revenue from vaccines once trial for children-use is completed, and (c) most importantly, new revenue stream from oral medication.  Further streams are also coming in from non-covid related medications approved recently. 

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论